fluoxetine has been researched along with Multiple System Atrophy Syndrome in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are no effective treatments for multiple system atrophy (MSA)." | 7.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| "There are no effective treatments for multiple system atrophy (MSA)." | 3.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rascol, O | 1 |
| Cochen de Cock, V | 1 |
| Pavy-Le Traon, A | 1 |
| Foubert-Samier, A | 1 |
| Thalamas, C | 1 |
| Sommet, A | 1 |
| Rousseau, V | 1 |
| Perez-Lloret, S | 1 |
| Fabbri, M | 1 |
| Azulay, JP | 1 |
| Corvol, JC | 1 |
| Couratier, P | 1 |
| Damier, P | 1 |
| Defebvre, L | 1 |
| Durif, F | 1 |
| Geny, C | 1 |
| Houeto, JL | 1 |
| Remy, P | 1 |
| Tranchant, C | 1 |
| Verin, M | 1 |
| Tison, F | 1 |
| Meissner, WG | 1 |
1 trial available for fluoxetine and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
Topics: Double-Blind Method; Fluoxetine; Humans; Multiple System Atrophy; Parkinson Disease; Quality of Life | 2021 |